PeptideStack
5.2kquestions
20kanswers
220users

clinical-trials

Page 21 of 32 · 745 questions tagged clinical-trials.

745 questions · sorted by votes · page 21 of 32

15 votes0 answers6k views
Is there any published stability data for semaglutide at 30 °C?

Conditions: semaglutide · 30 °C. I want to know whether there is evidence behind this or only repetition. I have checked the obvious registries and monographs without…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by greta_holzmann 23k · 6 months ago
15 votes2 answers4k views
What does ATTAIN-1 tell me about injection-site erythema at the 36 mg dose?

The case in front of me: ATTAIN-1 · injection-site erythema · 36 mg. I would like to know the limits of what can be inferred from this. What I am trying to avoid is…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
injection-site-reaction
injection-site-reaction

Local reactions: erythema, induration, pruritus and nodules. Their relationship to injection depth, diluent composition, benzyl alcohol…

49 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by coring_risk 27k · 4 months ago
14 votes 5 answers38k views
What does REDEFINE-1 tell me about nausea at the 2.4 mg dose?

For reference: REDEFINE-1 · nausea · 2.4 mg. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

55 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by samir_bennani 15k · 23 months ago
14 votes 5 answers34k views
What did the placebo arm of ATTAIN-1 report for early satiety?

For reference: ATTAIN-1 · early satiety. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
asked by kofi_mensah 18k · 2.1 years ago
14 votes 5 answers26k views
What does the mechanism of cagrilintide predict that REDEFINE-1 did not test?

Stated plainly: cagrilintide · REDEFINE-1. The empirical answer seems settled. The explanation does not. If the honest answer is that nobody knows, I would rather…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gip-receptor
gip-receptor

GIP receptor pharmacology, and the still-unsettled question of whether agonism or antagonism at GIPR is the metabolically useful direction.…

34 questions
amylin
amylin

Amylin and its analogues, most prominently cagrilintide, as a satiety mechanism orthogonal to incretin signalling. Includes the pharmacology of…

237 questions
asked by haze_check 9.3k · 16 months ago
14 votes5 answers20k views
What did the placebo arm of SURMOUNT-OSA report for nausea?

What I am working with: SURMOUNT-OSA · nausea. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

55 questions
asked by assay_blank 45k · 14 months ago
14 votes 5 answers17k views
How do I convert the SUSTAIN-6 hazard ratio into an absolute risk reduction?

I have three data points across nine months, which I hope is enough to see a trend. I can do the algebra. I am not confident about the conversion factors. If there is…

cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
asked by nadia_kowalczyk 20k · 2.3 years ago
14 votes 5 answers15k views
Do the trial populations say anything usable about sarcopenia risk?

The trend is what I care about; individual weeks are obviously noise. I would like to know whether this claim survives contact with evidence. If the answer is "nobody…

sarcopenia
sarcopenia

Clinically meaningful loss of muscle mass and function, particularly in older adults on treatment. Distinguishing a proportional reduction from a…

7 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
muscle-loss
muscle-loss

Loss of contractile tissue during energy deficit: what fraction of total loss is lean mass, why the commonly quoted figures are measurement…

39 questions
asked by Dr_Rosalind_Achebe 69k · 19 months ago
14 votes 3 answers14k views
How comparable are cagrilintide and semaglutide on the evidence available?

Setup, so nobody has to ask: cagrilintide · semaglutide. I have used one of these for a while and I am considering switching, which requires a reason. What I care…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
amylin
amylin

Amylin and its analogues, most prominently cagrilintide, as a satiety mechanism orthogonal to incretin signalling. Includes the pharmacology of…

237 questions
asked by u100_marks 52k · 9 months ago
14 votes 2 answers11k views
What does PIONEER-1 tell me about headache at the 25 mg dose?

For reference: PIONEER-1 · headache · 25 mg. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by leonid_marchuk 19k · 2.0 years ago
14 votes4 answers11k views
What does STEP 2 tell me about hair thinning at the 1 mg dose?

For reference: STEP 2 · hair thinning · 1 mg. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
hair-loss
hair-loss

Telogen effluvium following rapid weight loss versus a drug-attributable effect: the timing signature that distinguishes them, protein and…

50 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by t_oyelaran 79k · 14 months ago
14 votes 3 answers8.6k views
What did STEP 2 do with participants who could not tolerate a step?

I have been on a stable schedule for eleven weeks, so this is not a first-week question. I have the document in front of me and I can read the numbers. What I cannot…

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
asked by seven_day_half 31k · 9 months ago
14 votes5 answers8.2k views
What did the placebo arm of TRIUMPH-1 report for vomiting?

Concretely: TRIUMPH-1 · vomiting. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
asked by seamus_brady 15k · 3 months ago
14 votes 5 answers8.1k views
Is 10 mg weekly a defensible maintenance dose for ecnoglutide?

The particulars: 10 mg · ecnoglutide. I am at the decision point and I would rather think it through than improvise. I would rather spend money on measurement than on…

maintenance-dose
maintenance-dose

Staying put: the lowest dose that holds a result, the difference between the maximum studied dose and the maximum useful dose, and what the…

54 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
ecnoglutide
ecnoglutide

A long-acting GLP-1 receptor agonist with a cAMP-biased signalling profile. A niche tag, mostly used for mechanism questions about biased agonism…

223 questions
asked by marcus_thorbjorn 9.4k · 10 months ago
14 votes5 answers6.8k views
What is the reported incidence of dizziness on tirzepatide in SURPASS-2?

The specifics, since they change the answer: dizziness · tirzepatide · SURPASS-2. I have the document in front of me and I can read the numbers. What I cannot do is…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by RP_C18 105k · 9 months ago
14 votes 5 answers4.2k views
How do I convert the PIONEER-4 hazard ratio into an absolute risk reduction?

My laboratory results are from the same laboratory each time, drawn fasting, which I gather matters. Please show the division. I want to check my own against yours. I…

cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
asked by syringe_ninety 12k · 3 months ago
14 votes0 answers2.3k views
What did the placebo arm of STEP 2 report for constipation?

The particulars: STEP 2 · constipation. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably comfortable…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
constipation
constipation

Slowed transit as a consequence of delayed gastric emptying and reduced intake: incidence figures, fibre and hydration evidence, and why it often…

55 questions
asked by gel_pack_warm 13k · 5 months ago
13 votes3 answers33k views
How do I convert the STEP 8 hazard ratio into an absolute risk reduction?

This is a question about interpretation, not about whether to act — I will take action questions elsewhere. I have worked this out and I would like someone to find…

cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
asked by lipid_panel_q 36k · 2.4 years ago
13 votes5 answers24k views
What does STEP 5 tell me about vomiting at the 2.4 mg dose?

Stated plainly: STEP 5 · vomiting · 2.4 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by plate_count_9k 78k · 2.0 years ago
13 votes5 answers21k views
Is 25 mg weekly a defensible maintenance dose for oral semaglutide?

Conditions: 25 mg · oral semaglutide. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and I would like the…

maintenance-dose
maintenance-dose

Staying put: the lowest dose that holds a result, the difference between the maximum studied dose and the maximum useful dose, and what the…

54 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
asked by rosa_mendieta 8k · 18 months ago
13 votes 5 answers16k views
What does SOUL actually establish about a GLP-1 receptor agonist?

What I am working with: SOUL · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have the full…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
asked by siobhan_deasy 9.5k · 18 months ago
13 votes5 answers15k views
What is the reported incidence of nausea on a GLP-1 receptor agonist in STEP 8?

Stated plainly: nausea · a GLP-1 receptor agonist · STEP 8. I would like help reading this properly rather than being told what conclusion to reach. I have the full…

nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

55 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
asked by wren_calloway 23k · 19 months ago
13 votes 5 answers13k views
Is ATTAIN-1 a fair comparison of orforglipron against its comparator arm?

The specifics, since they change the answer: ATTAIN-1 · orforglipron. Somebody stated this to me confidently and I would like to check it before repeating it. I would…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by valentina_rossi 9.7k · 15 months ago
13 votes 5 answers12k views
What does TRIUMPH-1 actually establish about retatrutide?

Setup, so nobody has to ask: TRIUMPH-1 · retatrutide. I have read the primary source rather than the summary, which has left me with more questions. I understand the…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
retatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
asked by rune_thoresen 16k · 19 months ago